Benefits
Inflammatory signaling in laboratory and animal studies
In cultured immune cells, CBC lowered nitric oxide production, and in mice it eased chemically induced colon inflammation. In laboratory assays it switches on the CB2 receptor and a TRP channel tied to inflammation, and in human skin oil cells it reduced inflammatory messengers. These are laboratory and animal results; CBC has not been tested for inflammation in people.
Pain signaling in animal studies
In anaesthetized rats, CBC placed into a midbrain pain-control region quieted pain-signaling neurons and raised the threshold for a heat response, and raised the animals' own cannabinoid levels there. Blockers of CB1, adenosine A1 and TRPA1 prevented the effect. This is an anaesthetized-animal pain-pathway finding, not evidence of pain relief in people.
Mood-related behavior in animal studies
In two mouse tests used to screen antidepressant drugs, CBC lowered immobility, a behavior change the tests link to mood, at relatively high doses. A later study in stressed mice reported a similar change alongside lower stress-hormone and brain enzyme readings. These are animal screening results and do not show that CBC changes mood in people.
Skin oil cells in laboratory studies
In cultured human sebaceous gland cells, CBC lowered the excess oil production triggered by an acne-related fatty acid and, with other cannabinoids tested, reduced inflammatory messengers after an immune challenge. The cells were grown in a dish, not studied in people, and CBC has not been tested on skin in any human trial.
Gut muscle activity during inflammation in animal studies
In mice, CBC did not change normal gut movement but brought overactive gut movement back toward normal when the intestine was inflamed, through a route that did not depend on cannabinoid or TRPA1 receptors. This is an animal finding, and CBC has not been studied for digestive complaints in people.
Absorption when taken with CBD and THC
In the only human study, a cannabis oil containing CBD, THC and CBC was taken twice daily for a week. CBC appeared in the blood and, judged against the dose given, seemed to be taken up at least as readily as the CBD and THC in the same oil. The study measured only blood levels, not any health effect, and CBC was never given on its own.
Mechanism of action
A non-intoxicating minor cannabinoid
CBC is one of the more abundant minor cannabinoids in some hemp varieties. The plant makes it from cannabichromenic acid, which traces back to the same precursor that becomes THC and CBD. It binds the brain's CB1 receptor only weakly, which fits its lack of a high.
Activates the CB2 receptor
In laboratory cell tests, CBC switched on the CB2 cannabinoid receptor, which sits mainly on immune cells, acting more strongly there than THC while leaving the brain's CB1 receptor largely untouched. Researchers have linked this CB2 action to the anti-inflammatory effects seen in cell and animal work.
TRP channels and endocannabinoid tone
CBC activates TRPA1, a sensory channel involved in pain and inflammation, and slows the breakdown and reuptake of the body's own cannabinoids, which can raise their levels. In animal pain studies adenosine A1 signaling was also involved. These targets come from laboratory and animal experiments.
Mostly preclinical, with little human data
Almost everything known about how CBC behaves comes from cells and animals. The only human work measured how much CBC reached the blood when it was taken with CBD and THC, and found it was absorbed. How these receptor and channel actions translate into effects in people has not been studied.
Clinical trials
Secondary analysis of a randomized trial of an oral cannabis oil containing CBD, THC and CBC taken every 12 hours for 7 days, measuring blood CBC levels; the authors worked for a cannabis company (Peters et al. 2022, Eur J Clin Pharmacol).
43 adults randomized to one of four CBD/THC/CBC dose levels (6.6 to 26.4 mg CBC a day) or placebo.
CBC was measurable in blood after single and repeated dosing, with peak levels about 1.6 to 4.3 hours after a dose. Judged against the amount given, CBC appeared to be absorbed at least as readily as the CBD and THC in the same oil. The study measured only blood levels, not any health outcome, and CBC was never given on its own.
Laboratory study comparing several plant cannabinoids in the mouse forced swim and tail suspension tests, after first screening doses for sedation and catalepsy (El-Alfy et al. 2010, Pharmacol Biochem Behav).
Mice given CBC at 20, 40 or 80 mg/kg by injection.
CBC lowered immobility in the forced swim test at 20 mg/kg and produced a dose-dependent drop in the tail suspension test at 40 and 80 mg/kg, a pattern these tests link to antidepressant drugs. CBG and CBN did not. This is an animal screening result, not evidence in people.
Study recording pain-control neuron activity and heat-response latency in anaesthetized rats after CBC was injected into a midbrain region (Maione et al. 2011, Br J Pharmacol).
Anaesthetized rats; CBC given at up to 6 nmol into the periaqueductal grey.
CBC reduced the firing of pain-signaling neurons and raised the heat-response threshold, with the largest effect at 6 nmol, and raised the animals' own cannabinoid levels in that region. The response was blocked by CB1, adenosine A1 and TRPA1 blockers but not a TRPV1 blocker. An anaesthetized-animal pain-pathway result.
Animal study combining computer target prediction with testing of CBC against the antidepressant imipramine in mice exposed to 3 weeks of unpredictable mild stress (Sharma et al. 2025, Naunyn Schmiedebergs Arch Pharmacol).
Male mice given CBC 10 or 20 mg/kg or imipramine 15 mg/kg for 21 days.
CBC 20 mg/kg lowered immobility in stressed mice, similar to imipramine, without changing movement, and lowered stress-hormone and brain enzyme readings. Computer modeling pointed to the CB2 receptor as the main shared target. The authors called for further models and clinical study. Animal evidence only.
Laboratory study of several non-intoxicating cannabinoids on cultured human sebaceous gland cells, measuring oil production and inflammatory messengers (Oláh et al. 2016, Exp Dermatol).
Cultured human SZ95 sebocytes (a cell line).
CBC suppressed basal oil (lipid) production and lowered the excess lipid production triggered by an acne-related fatty acid, and with the other cannabinoids tested it reduced inflammatory messengers after an immune challenge. High concentrations caused cell death. The authors suggested CBC as a possible future acne agent. Cell-culture evidence only.
Study of CBC on intestinal movement in normal mice and in mice with chemically inflamed intestines, with isolated gut tissue tested in an organ bath (Izzo et al. 2012, Br J Pharmacol).
Mice, with inflammation induced by croton oil; isolated ileum was also tested.
CBC did not change gut movement in healthy mice but brought inflammation-driven overactive movement back toward normal. The effect did not depend on cannabinoid or TRPA1 receptors. Animal and isolated-tissue evidence only.
Study of CBC on cultured immune cells (macrophages) and in a chemically induced mouse model of colon inflammation (Romano et al. 2013, Br J Pharmacol).
Mouse peritoneal macrophages in culture and mice with DNBS-induced colitis.
CBC lowered nitric oxide production by activated macrophages and eased colon inflammation in mice, as judged by a tissue enzyme marker, microscopy and staining. Its actions involved TRPA1 and were shaped by cannabinoid receptor signaling. Animal and cell evidence only.